193 related articles for article (PubMed ID: 31311023)
1. Risk of Ovarian Malignancy Algorithm versus Risk Malignancy Index-I for Preoperative Assessment of Adnexal Masses: A Systematic Review and Meta-Analysis.
Chacón E; Dasí J; Caballero C; Alcázar JL
Gynecol Obstet Invest; 2019; 84(6):591-598. PubMed ID: 31311023
[TBL] [Abstract][Full Text] [Related]
2. Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women.
Davenport C; Rai N; Sharma P; Deeks JJ; Berhane S; Mallett S; Saha P; Champaneria R; Bayliss SE; Snell KI; Sundar S
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD011964. PubMed ID: 35879201
[TBL] [Abstract][Full Text] [Related]
3. Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal.
Melo Â; Veríssimo R; Farinha M; Martins NN; Martins FN
J Obstet Gynaecol; 2018 Nov; 38(8):1140-1145. PubMed ID: 29884096
[TBL] [Abstract][Full Text] [Related]
4. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass.
Al Musalhi K; Al Kindi M; Al Aisary F; Ramadhan F; Al Rawahi T; Al Hatali K; Mula-Abed WA
Oman Med J; 2016 Sep; 31(5):336-44. PubMed ID: 27602187
[TBL] [Abstract][Full Text] [Related]
7. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526
[TBL] [Abstract][Full Text] [Related]
8. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
Lycke M; Kristjansdottir B; Sundfeldt K
Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
[TBL] [Abstract][Full Text] [Related]
9. Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study.
Choi HJ; Lee YY; Sohn I; Kim YM; Kim JW; Kang S; Kim BG
Curr Probl Cancer; 2020 Apr; 44(2):100508. PubMed ID: 31708114
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study.
Piovano E; Cavallero C; Fuso L; Viora E; Ferrero A; Gregori G; Grillo C; Macchi C; Mengozzi G; Mitidieri M; Pagano E; Zola P
Ultrasound Obstet Gynecol; 2017 Sep; 50(3):395-403. PubMed ID: 27706929
[TBL] [Abstract][Full Text] [Related]
11. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis.
Kaijser J; Sayasneh A; Van Hoorde K; Ghaem-Maghami S; Bourne T; Timmerman D; Van Calster B
Hum Reprod Update; 2014; 20(3):449-62. PubMed ID: 24327552
[TBL] [Abstract][Full Text] [Related]
12. [Investigating the predictive value of RMI and ROMA indices in patients with ovarian tumors of uncertain dignity].
Krascsenits G; Balázs B; Dudnyikova A; Purcsi K; Orosz E; Pete I
Magy Onkol; 2016 Nov; 60(4):320-327. PubMed ID: 27898751
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses].
Janas L; Głowacka E; Wilczyński JR; Malinowski A; Nowak M
Ginekol Pol; 2015 Mar; 86(3):193-7. PubMed ID: 25920309
[TBL] [Abstract][Full Text] [Related]
15. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the diagnostic accuracy of International Ovarian Tumor Analysis simple rules and the risk of malignancy index to discriminate between benign and malignant adnexal masses.
Auekitrungrueng R; Tinnangwattana D; Tantipalakorn C; Charoenratana C; Lerthiranwong T; Wanapirak C; Tongsong T
Int J Gynaecol Obstet; 2019 Sep; 146(3):364-369. PubMed ID: 31206642
[TBL] [Abstract][Full Text] [Related]
17. Role of a risk of malignancy index in clinical approaches to adnexal masses.
Simsek HS; Tokmak A; Ozgu E; Doganay M; Danisman N; Erkaya S; Gungor T
Asian Pac J Cancer Prev; 2014; 15(18):7793-7. PubMed ID: 25292065
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter?
Lennox GK; Eiriksson LR; Reade CJ; Leung F; Mojtahedi G; Atenafu EG; Ferguson SE; Murphy J; Diamandis EP; Kulasingam V; Bernardini MQ
Int J Gynecol Cancer; 2015 Jun; 25(5):809-14. PubMed ID: 25855958
[TBL] [Abstract][Full Text] [Related]
19. Value of the Copenhagen index in the diagnosis of malignant adnexal tumors: A meta-analysis.
Yue X; Yue Z; Wang Y; Dong Z; Yang H; Yue S
Int J Gynaecol Obstet; 2023 Feb; 160(2):506-515. PubMed ID: 35696160
[TBL] [Abstract][Full Text] [Related]
20. Should cut-off values of the risk of malignancy index be changed for evaluation of adnexal masses in Asian and Pacific populations?
Yavuzcan A; Caglar M; Ozgu E; Ustun Y; Dilbaz S; Ozdemir I; Yildiz E; Gungor T; Kumru S
Asian Pac J Cancer Prev; 2013; 14(9):5455-9. PubMed ID: 24175841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]